Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1987 28
1988 15
1989 52
1990 117
1991 401
1992 248
1993 358
1994 425
1995 424
1996 480
1997 486
1998 719
1999 598
2000 667
2001 785
2002 863
2003 964
2004 1038
2005 1227
2006 1111
2007 1033
2008 1092
2009 1134
2010 1154
2011 1201
2012 1197
2013 1197
2014 1202
2015 1190
2016 1204
2017 1215
2018 1225
2019 1258
2020 1323
2021 1388
2022 1235
2023 1214
2024 1268
2025 1329
2026 1112
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,047 results

Results by year

Filters applied: . Clear all
Page 1
Tacrolimus - Pharmacokinetic Considerations for Clinicians.
Schutte-Nutgen K, Tholking G, Suwelack B, Reuter S. Schutte-Nutgen K, et al. Curr Drug Metab. 2018;19(4):342-350. doi: 10.2174/1389200219666180101104159. Curr Drug Metab. 2018. PMID: 29298646 Review.
BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal transplantation (RTx). ...We therefore review current state of the art aspects of tacrolimus pharmacokinetics including genetics or diffe …
BACKGROUND: The calcineurin inhibitor tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after renal tran …
Clinical pharmacokinetics of tacrolimus.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Venkataramanan R, et al. Clin Pharmacokinet. 1995 Dec;29(6):404-30. doi: 10.2165/00003088-199529060-00003. Clin Pharmacokinet. 1995. PMID: 8787947 Review.
Currently, most of the pharmacokinetic data available for tacrolimus are based on an enzyme-linked immunosorbent assay method, which does not distinguish tacrolimus from its metabolites. ...Tacrolimus is extensively bound to red blood cells, with a mean blood …
Currently, most of the pharmacokinetic data available for tacrolimus are based on an enzyme-linked immunosorbent assay method, which …
[Tacrolimus].
Uemoto S. Uemoto S. Nihon Rinsho. 2005 May;63 Suppl 5:673-7. Nihon Rinsho. 2005. PMID: 15954428 Review. Japanese. No abstract available.
Ranolazine-tacrolimus interaction.
Pierce DA, Reeves-Daniel AM. Pierce DA, et al. Ann Pharmacother. 2010 Nov;44(11):1844-9. doi: 10.1345/aph.1P297. Epub 2010 Sep 28. Ann Pharmacother. 2010. PMID: 20876828
OBJECTIVE: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus concentrations within 24 hours of initiating ranolazine. ...CONCLUSIONS: We suggest that the eventual 70% decrease in tacrolimus …
OBJECTIVE: To report the case of a kidney allograft recipient on a stable regimen of tacrolimus who exhibited increased tacrolimus …
Tacrolimus.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2001 Dec 15;58(24):2376-7. doi: 10.1093/ajhp/58.24.2376. Am J Health Syst Pharm. 2001. PMID: 11794952 No abstract available.
Tacrolimus Fujisawa.
Gewirtz AT, Sitaraman SV. Gewirtz AT, et al. Curr Opin Investig Drugs. 2002 Sep;3(9):1307-11. Curr Opin Investig Drugs. 2002. PMID: 12498005 Review.
By March 2002, tacrolimus had entered phase III trials for inflammatory bowel disease (IBD) in Japan [442503]. This evaluation will focus on the development of tacrolimus for this indication....
By March 2002, tacrolimus had entered phase III trials for inflammatory bowel disease (IBD) in Japan [442503]. This evaluation will f …
[Biosynthesis of immunosuppressant tacrolimus: a review].
Jin L, Lu D, Xing M, Wang X, Liu Z, Zheng Y. Jin L, et al. Sheng Wu Gong Cheng Xue Bao. 2023 Aug 25;39(8):3095-3110. doi: 10.13345/j.cjb.220994. Sheng Wu Gong Cheng Xue Bao. 2023. PMID: 37622350 Free article. Review. Chinese.
The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This review summarizes the progress made in tacrolimus biosynthesis via modification of metabolic pathways and control of fermentation pr …
The research on tacrolimus production was mainly focused on biosynthesis methods, within which there are still some bottlenecks. This …
Exploring the neuroregenerative potential of tacrolimus.
Saffari TM, Bedar M, Zuidam JM, Shin AY, Baan CC, Hesselink DA, Hundepool CA. Saffari TM, et al. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1047-1057. doi: 10.1080/17512433.2019.1675507. Epub 2019 Oct 22. Expert Rev Clin Pharmacol. 2019. PMID: 31575290 Review.
Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacrolimus has also shown to have neuroregenerative properties. ...The aim of this article is to review current evidence regarding the use of …
Introduction: The clinical use of tacrolimus is characterized by many side effects which include neurotoxicity. In contrast, tacro …
Modified release tacrolimus.
First MR, Fitzsimmons WE. First MR, et al. Yonsei Med J. 2004 Dec 31;45(6):1127-31. doi: 10.3349/ymj.2004.45.6.1127. Yonsei Med J. 2004. PMID: 15627307 Free article. Review.
Modified Release (MR) tacrolimus is an extended release formulation of tacrolimus (Prograf) administered once daily in the morning. ...Subsequently, pharmacokinetic studies were performed in stable kidney and liver transplant recipients converted from Prograf bid to …
Modified Release (MR) tacrolimus is an extended release formulation of tacrolimus (Prograf) administered once daily in the mor …
Tacrolimus: a new immunosuppressive agent.
Kelly PA, Burckart GJ, Venkataramanan R. Kelly PA, et al. Am J Health Syst Pharm. 1995 Jul 15;52(14):1521-35. doi: 10.1093/ajhp/52.14.1521. Am J Health Syst Pharm. 1995. PMID: 7552894 Review.
Fewer reports have been published regarding tacrolimus use in other types of transplantation, but the results show that tacrolimus may be a useful alternative to cyclosporine. The major adverse effects of tacrolimus therapy are nephrotoxicity and neurotoxicit …
Fewer reports have been published regarding tacrolimus use in other types of transplantation, but the results show that tacrolimus …
32,047 results
You have reached the last available page of results. Please see the User Guide for more information.